KB-1336

1K17044-hIgG1

33669

Background of 1K17044-hIgG1

CCR8 is a member of the chemokine receptor family and functions as a G-protein coupled receptor. Extensive research has revealed that CCR8 exhibits specific expression on regulatory T cells (Treg) infiltrating tumors, as well as on Th2 cells and tumor cells. The monoclonal antibody 1K17044-hIgG1, currently under development as an anti-CCR8 therapeutic, has demonstrated the capacity to induce discernible depletion of CCR8+ Treg cells in human tumor explants. This CCR8+ Treg depletion has translated into robust antitumor activity when administered as a standalone treatment and in combination with anti-PD-1 therapy in murine tumor models. These findings provide substantial support for further clinical exploration of CCR8 depletion, especially in conjunction with immune checkpoint blockade, as an innovative approach to cancer immunotherapy.

Specifications

Catalog Number	KB-1336
Antibody Name	1K17044-hIgG1
Isotype	Human IgG1,kappa
Target	CCR8
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	FACS
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

PB Silver, et al., Retina-specific T regulatory cells bring about resolution and maintain remission of autoimmune uveitis. J Immunol 194, 3011–3019 (2015).
J van Loosdregt, et al., Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity. Immunity 39, 259–271 (2013).